Genenta Science S.p.A.
GNTANASDAQHealthcareBiotechnology
Previous close
$1.26
+$0.07 · +5.88%
GNTA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
34
Expensive
Momentum
45
Neutral
Sentiment
52
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteGenenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IT
- CEO
- Pierluigi Paracchi
- Listed since
- Dec 15, 2021
- Employees
- 9
Market position
Day range
Current $1.26
52-week range
Current $1.26
- Open
- $1.22
- Previous close
- $1.19
- Volume
- 28.51K
- 0.02× average
- Average volume
- 1.48M
- Average daily volume
- Market cap
- 24.12M USD
- Beta
- 0.77
- Market reference 1
- 50-day average
- $1.54
- -18.18% below average
- 200-day average
- $1.2724
- -0.97% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -3.27×
- P/B (TTM)
- 1.05×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0.35×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 26.97K USD | 46.51K USD | 41.71K USD | 6K USD | 5.1K USD |
| Gross profit | −26.97K USD | −46.51K USD | −41.71K USD | −6K USD | −5.1K USD |
| Research and development | 2.59M USD | 5.03M USD | 6.36M USD | 5.21M USD | 3.53M USD |
| Selling, general, and administrative | 3.72M USD | 5.13M USD | 5.12M USD | 5.57M USD | 2.39M USD |
| Operating expenses | 6.32M USD | 10.15M USD | 11.48M USD | 10.78M USD | 5.92M USD |
| Interest income | 968.7K USD | — | — | — | — |
| Interest expense | 384.21K USD | — | — | — | — |
| Depreciation and amortization | 26.97K USD | 46.51K USD | 41.71K USD | 6K USD | 5.1K USD |
| Operating income | −6.34M USD | −10.2M USD | −11.53M USD | −10.79M USD | −5.93M USD |
| Net income | −6.27M USD | −9.31M USD | −11.44M USD | −8.28M USD | −5.76M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 75%
- 3 beats, 0 misses, 1 met estimate
- Average EPS surprise
- +9.39%
- 4 comparable reports
- Latest EPS result
- -0.36
- Estimate -0.36 · Met by 0.00%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
GNTA peers
Continue in GoAI
Research GNTAresearch.disclaimer